Atrial fibrillation ablation
Ablazione della fibrillazione atriale
Transcatheter ablation can be used in case of atrial fibrillation (AF) not controlled by medical therapy due to lack of efficacy or poor tolerability.The procedure is however associated with the risk of periprocedural events and therefore requires particular attention to systemic anticoagulant therapy. In this clinical setting dabigatran may represent a valid therapeutic option to ensure adequate patient protection during the ablation procedure, as demonstrated by the results of the RE-CIRCUIT study. Here we describe an elderly patient, treated for hypertension, with a slightly impaired renal function, a long history of highly symptomatic paroxysmal AF resistant to antiarrhythmic drugs. It describes the common clinical practice prior to the publication of the RE-CIRCUIT study results, which support performing the AF ablation procedure without interrupting the anticoagulant therapy in place with dabigatran. It also highlights the potential efficacy of dabigatran in the treatment of endoauricular thrombus in patients with FA, for whom the currently recommended treatment is bridging with LMWH and the initiation of oral anticoagulant therapy with VKA, which however may be ineffective, as in this case (Diabetology).
Copyright (c) 2018 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors contributing to AboutOpen agree to publish their articles under the Creative Commons NonCommercial 4.0 International License (CC BY-NC 4.0), which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.